Visanne 2mg TABLET
PDF Leaflet Revision Date: 01 March 2022
Clinical Summary
Quick overview from the medicine insert
Indication
Long-term treatment of endometriosis.
Dosage (summary)
1 tablet daily, starting on day 1 of the menstrual cycle, without breaks.
Special Populations
- Adolescents (12+ years)
- Hepatic impairment
- Renal impairment
Pregnancy & Breastfeeding
Not recommended during pregnancy or breastfeeding.
Key Drug Interactions
- CYP3A4 inducers (e.g., phenytoin, rifampicin)
- CYP3A4 inhibitors (e.g., azole antifungals)
Contraindications
- Venous thromboembolic disorder
- Cardiovascular diseases
- Severe hepatic disease
- Liver tumors
- Undiagnosed vaginal bleeding
Common side effects
- Weight changes
- Depressed mood
- Headache
- Nausea
- Breast discomfort
Counselling Points
- Take at the same time daily
- Monitor for signs of depression
- Use non-hormonal contraception to prevent pregnancy
Serious warnings
- Increased risk of venous thromboembolism
- Potential for decreased bone mineral density in adolescents
Important Disclaimer
The Visanne 2mg TABLET professional information leaflet below is the property of Bayer and is provided on Medinsert exactly as issued, with no.. alterations or editorial changes. We make every effort to keep content current by updating documents as soon as new versions become available. Medinsert serves as a trusted access point for healthcare professionals, but does not replace official sources or clinical judgement. For more details, please read our full disclaimer. read more>>
Healthcare Professionals Only
This content is for registered healthcare professionals
Sign in or create a free account to read the full package insert.
Free for HPCSA-registered professionals. Powered by Medinsert.
